admin | February 25, 2025
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress for Preclinical Data on Novel Allosteric BCR-Abl Inhibitor Tern-701
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
